{
  "label": "q_cs03_q18_temporal",
  "artifact_type": "question",
  "artifact_id": "sha256:c829f3f2fb967e10ad2b9ff273f03ad140fc79e3ad30cb869e3342042394f3a0",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:cab0ed69f1fa476255e68bf8c3e4cc9b8de1271b593421292819215fb07dd0fd",
    "sha256:4f19c245d677c1fe3130a0d7489797849b719a5e5c06408f2c5455f12ba2dbc7"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:01:44.859993",
  "content": "{\n  \"question_id\": \"cs03_q18_temporal\",\n  \"scope_id\": \"clinical_signal_03\",\n  \"checkpoint_after\": 15,\n  \"question_type\": \"temporal\",\n  \"prompt\": \"When did the first hepatic enzyme elevations appear relative to drug exposure initiation?\",\n  \"ground_truth\": {\n    \"canonical_answer\": \"Hepatic enzyme elevations first appeared during the early signal phase, approximately weeks 9-10 of the trial, several weeks after subjects began receiving LNS-4821 with concomitant statin therapy.\",\n    \"required_evidence_refs\": [\n      \"clinical_signal_03_ep_010\",\n      \"clinical_signal_03_ep_013\"\n    ],\n    \"key_facts\": [\n      \"ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases\",\n      \"multi-site signal distribution rules out site-specific confounders as causal explanation\",\n      \"ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event\"\n    ]\n  }\n}",
  "metadata": {
    "question_id": "cs03_q18_temporal",
    "question_type": "temporal",
    "checkpoint_after": 15,
    "scope_id": "clinical_signal_03",
    "layer_name": "questions",
    "layer_level": 3,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "161c0fab5bfb17c8d383c9fc2e7d9a8e8d78cb9207842d17ff5d292bb2eb0e86",
      "components": {
        "transform": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
        "inputs": "356f57bd91d5841f"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
      "components": {
        "transform_id": "3176c030aaa3a69e",
        "source": "929fe273ac2dab06",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}